To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Metastatic Breast Cancer

Martha Carlson
How we think about things can have a powerful impact on our experiences. Here's why that matters for people with cancer.
Jason M. Broderick
The Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) for use in combination with a hormonal therapy for initial treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
Martha Carlson
Using some simple reminders that life is still happening can help put cancer anxiety and fear back where they belong.
Martha Carlson
Individual advocates and larger organizations offer hope as they help us understand what future treatments are in the pipeline. 
Brielle Urciuoli
Until recently, Herceptin, which is used to treat patients with metastatic breast cancer, was fully covered under Humana’s South Florida Medicare Advantage plans. But, after taking it off the preferred drug list, patients will now be responsible for 20 percent of the drug’s cost, better aligning South Florida’s plans with Humana’s other Medicare Advantage plans.
Kristie L. Kahl
As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.
Jason M. Broderick
Lynparza (olaparib) was granted approval by the Food and Drug Administration (FDA) for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Also, patients who have HR-positive disease should have prior endocrine therapy or they would not be considered appropriate for such treatment.
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, consider the use of CDK4/6 inhibitors in metastatic breast cancer.
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, discuss stabilized disease in metastatic breast cancer and reinforce the value in routine scans, tumor marker tests, and regular follow up with clinicians.
Martha Carlson
Treatment for metastatic cancer can mean asking a tough question every single day.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other